Teva Pays $120M to Distribute Rival Cancer Drug

Feb 19, 2015

Nasdaq

Teva Pharmaceutical Industries has agreed to a potential $120M licensing agreement allowing it to promote and distribute Eagle Pharmaceuticals' cancer drug EP-3102 -- a potential competitor to Teva's own treatment -- in the U.S.

EP-3102 is a rapid-infusion product that treats chronic lymphocytic leukemia and a type of non-Hodgkin's lymphoma. It is similar to Teva's chronic lymphocytic leukemia treatment Treanda, but has a substantially shorter infusion time.

Eagle has previously submitted a new drug application for EP-3102 to the U.S. FDA and requested priority review. The drug had received orphan-drug designation.

Read the Nasdaq press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments